Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Insight Lifetech Debuts on Shanghai STAR Market with $3 Billion Valuation, Breaking Import Monopoly in Cardiovascular Imaging

Fineline Cube Feb 6, 2026
Company Deals

Knature Biopharmaceutical Files Hong Kong IPO to Advance Mitochondrial Medicine and NAD+ Therapeutics

Fineline Cube Feb 6, 2026
Company Deals Digital

XtalPi Partners with Visen Pharma to Accelerate AI‑Driven Endocrine Drug Discovery

Fineline Cube Feb 6, 2026
Company Deals

Shanghai Pharma to Divest 30% Stake in Sino-American Squibb for $147M

Fineline Cube Feb 6, 2026
Company Deals

Everest Medicines Licenses Micot’s MT1013 for Secondary Hyperparathyroidism in $178M Deal

Fineline Cube Feb 5, 2026
Policy / Regulatory

Guangdong Unveils Expanded 2025 Greater Bay Area Access List for 115 Hong Kong and Macao Drugs and Devices

Fineline Cube Feb 9, 2026
Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Fineline Cube Feb 9, 2026
Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Fineline Cube Feb 9, 2026
Company Deals Digital

Omron Healthcare and JD Healthcare Form Partnership to Innovate Chronic Disease Management

Fineline Cube May 15, 2023

At the China International Medical Equipment Fair (CMEF), Omron Healthcare, a leading provider of healthcare...

Company Deals

LaNova Medicines and AstraZeneca Ink Global Licensing Deal for GPRC5D-Targeting ADC LM-305

Fineline Cube May 15, 2023

Shanghai-based LaNova Medicines Ltd, a developer of cancer therapies, has announced a significant global licensing...

Company Deals

ExoRNA Bio Secures Tens of Millions in Financing to Advance Huntington’s Disease Pipeline

Fineline Cube May 15, 2023

ExoRNA Bio, a Shenzhen-based central nervous system (CNS) drug developer, has reportedly raised tens of...

Company Deals

Luye Pharma’s Boan Biotechnology Partners with GenScript on GenCircle dsDNA Development

Fineline Cube May 15, 2023

Shandong Boan Biotechnology Co., Ltd, a controlling subsidiary of China-based Luye Pharma Group (HKG: 2186),...

Company Drug

Betta Pharmaceuticals and EyePoint Pharmaceuticals Submit EYP-1901 for NMPA Review

Fineline Cube May 15, 2023

China’s Betta Pharmaceuticals (SHE: 300558) has announced that the clinical trial filing for its EYP-1901...

Policy / Regulatory

NMPA Releases 68th Batch of Reference Drugs for Generic Quality Consistency Evaluation

Fineline Cube May 15, 2023

The National Medical Products Administration (NMPA) has released the 68th batch of reference drugs for...

Company Medical Device

Basecare Medical to Acquire BMX Holdco for $40 Million, Expanding IVF Portfolio

Fineline Cube May 15, 2023

China-based in vitro fertilization (IVF) specialist, Suzhou Basecare Medical Co., Ltd (HKG: 2170), has announced...

Company Deals

Nona Biosciences Partners with PharmaEssentia for Harnessing Harbor Mice Technology

Fineline Cube May 12, 2023

Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has announced a strategic...

Company Deals

First Condor Biotechnology Secures Tens of Millions in Pre-Series A Financing for CAR-T Cell Trials

Fineline Cube May 12, 2023

First Condor Biotechnology, a Guangdong-based cell therapy developer, has reportedly secured tens of millions of...

Policy / Regulatory

China’s NHC and 13 Bureaus Launch Campaign to Rectify Pharmaceutical and Medical Services Practices

Fineline Cube May 12, 2023

The National Health Commission (NHC) along with 13 other bureaus has jointly released a notification...

Company

Bayer Q1 2023 Financial Report: Sales Dip Amid Regional Challenges and COVID-19 Impact

Fineline Cube May 12, 2023

Germany-based Bayer (ETR: BAYN) has released its financial report for the first quarter of 2023,...

Company Drug

Wuhan Institute’s Hexavalent Rotavirus Vaccine on Track for Priority Review by CDE

Fineline Cube May 12, 2023

The Center for Drug Evaluation (CDE) website has indicated that Wuhan Institute of Biological Products...

Company Drug

Kintor Pharmaceutical’s KX-826 Shows Promise in Phase II Study for Male Androgenetic Alopecia

Fineline Cube May 12, 2023

China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced the conclusion of a randomized, double-blind, placebo-controlled...

Company Deals Digital

ZhenGe Biotech Partners with NNIT for Advanced Digitalization in Drug Development

Fineline Cube May 12, 2023

ZhenGe Biotech, a China-based Contract Development and Manufacturing Organization (CDMO), has entered into a strategic...

Drug Legal / IP

CNIPA Releases Patent Linkage Decisions, Paving Way for Generic Drugs in China

Fineline Cube May 11, 2023

The China National Intellectual Property Administration (CNIPA) has released the latest batch of completed patent...

Company Drug

Guangdong Taienkang’s CKBA Ointment for Vitiligo Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Guangdong Taienkang Pharmaceutical Co., Ltd, (SHE: 301263), a China-based pharmaceutical company, has announced that the...

Company Drug

Mabwell’s B7-H3 Targeting ADC 7MW3711 Accepted for Review by China’s NMPA

Fineline Cube May 11, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a China-based biopharmaceutical company, has announced that its...

Company Drug

CStone Pharmaceuticals’ Partner Servier Secures EU Approvals for IDH1 Inhibitor Tibsovo

Fineline Cube May 11, 2023

CStone Pharmaceuticals’ (HKG: 2616) French partner, Servier, has announced receiving two new indication approvals for...

Company Drug

Innovent Biologics’ Mazdutide Showcases Weight Loss Efficacy in Phase II Study for Chinese Adults

Fineline Cube May 11, 2023

China-based Innovent Biologics Inc., (HKG: 1801), has announced that a Phase II clinical study assessing...

Policy / Regulatory

Beijing Medical Insurance Bureau Announces Key Healthcare Initiatives and BMI Expansion

Fineline Cube May 11, 2023

The Beijing Municipal Medical Insurance Bureau has released a notification outlining key tasks for the...

Posts pagination

1 … 482 483 484 … 621

Recent updates

  • Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market
  • Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market
  • Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego
  • Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer
  • Gilead’s Kite Pharma Secures FDA Label Expansion for Yescarta in Primary CNS Lymphoma
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Delonix Bioworks’ DX-104 Becomes First China-Approved Engineered OMV Vaccine, Targets $1.3 Billion MenB Market

Company Medical Device

Peijia Medical Files CE Mark for GeminiOne TEER System in European Mitral Regurgitation Market

Company

Novartis Breaks Ground on $23 Billion US Biomedical Research Center in San Diego

Company Drug

Sino Biopharm Completes Phase III Enrollment for LM-302 ADC in Gastric Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.